Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q1 FY2025 Earnings Presentation
25 slides from Poly Medicure's earnings presentation, Jul 24, 2024
Slide 1: Submission of Investor's Presentation (exchange cover letter)
Poly rviedicure Limited Regd. Office : 232 B. 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110 020 (INDIA) -~:» IPOLYMED T:+91-ll-33550700, 47317000 E: info@polymedicure .com W: polymedicure.com CIN : L40300DL1995PLC066923 Date: 24 th July, 2024 Scrip Code: - 531768 Scrip Code:- POLYME
Slide 2: Investor's Presentation, Poly Medicure Ltd., July 2024
Investor’s Presentation Poly Medicure Ltd. July 2024
Slide 3: Forward Looking Statement
Forward Looking Statement This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or
Slide 4: Polymed at a Glance
We are commanding a formidable presence in the medical devices space Polymed at a Glance 12 12 Manufacturing Plants Specialities Across 4 countries 125+ 200+ ••••••• ••••••••••• ••••••••••••• •••• • ••••• • • • • • ••••••••••••••• •••••••••••• • •• • ••••••• ••••• • •• ••• • ••• • ••• ••••• ••••••••
Slide 5: Navigating Our Journey: Polymed's Path of Milestones and Triumphs
Navigating Our Journey Polymed's Path of Milestones and Triumphs 1997 2004 2009 2014 2018 2020 2023 2025 Commencement Faridabad China Plant New Plant Renal Care New Plant in 4 New Plants Gamma of Manufacturing Plant 2 -Poly Medicure (Dialysis) IMT Faridabad Expansion in Sterilization SEZ Jaipur Fari
Slide 6: Comprehensive Integration: Our Solutions Enhance Care Across the Hospital Spectrum
Comprehensive Integration Our Solutions Enhance Care Across the Hospital Spectrum IPD ICU Blood Bank Emergency Dialysis Unit Operation Theatre Chemotherapy Pathology Lab Day Unit Specialty Treatment Units Cath Lab Gaestrontology, Urology -; :, POLYMED
Slide 7: Our Innovations Deliver Vital Care to Key Clinical Specialties
Our Innovations Deliver Vital Care to Key Clinical Specialties Cardiology Anaesthesia & Respiratory Care Transfusion System Oncology Vascular Access Infusion Therapy Gastroenterology Diagnostics Urology Dialysis & Renal Care Surgery & Wound Drainage Critical Care -; :, POLYMED
Slide 8: Diving into Our Product Portfolio
Diving into Our Product Portfolio I ,' --------------------------------------~-- -------------~-.-------------- ' . / . '\ I I Vascular -+ I I I Access Mini Mid Peripherally Inserted Peripherally inserted I I I Central Venous Safety Introducer Safety Winged /I IV Cannula Arterial Catheter Catheters
Slide 9: Product Portfolio: Cardiology, Surgery, Anesthesia & Respiratory Care
Cardiology I Diagnostic Catheter PTCA Balloon PTCA Balloon Hydrophilic Guidewire PTFE Coated Guidewire I .... _____________ _ Dilation Catheter SC Dilation Catheter NC Guiding Catheter I I ' --------------------------------------------------------------------------------; Surgery and Wound ( _) Clos
Slide 10: Value Creation Through Innovation and Streamlined Operational Models
Value Creation Through Innovation and Streamlined Operational Models Template GROW INNOVATE SCALE ▪ Foster sustainable revenue expansion, Striving for Margin ▪ Strategic Investments in ▪ Enhancing Manufacturing Growth High-Growth Areas - Capacities to global scale. ▪ Build direct presence in key Car
Slide 11: The Polymed's Ecosystem
The Polymed’s Ecosystem Clinical Support Distribution Network Sales & Marketing Product Concept f Product Product Design Manufacturing Rapid Prototyping Product Packaging Regulatory Sterilization Compliance ♦ ♦ Tool Design Tool Manufacturing -;:» POLYMED
Slide 12: Polymed's Robust Manufacturing Footprint
Polymed's Robust Manufacturing Footprint 12 State-of-the-Art Facilities across 3 continents 117,Faridabad, India IMT 1,Faridabad, India SEZ 2, Jaipur, India Laiyang-qingdao, 104-105,Faridabad Amaro, Italy Haridwar Plant, India IMT 2, Faridabad 115-116, Faridabad SEZ 1 Jaipur, India R & D Centre, Ind
Slide 13: Mastering Manufacturing
Mastering Manufacturing Striving Towards Operational Excellence -; :, POLYMED
Slide 14: Navigating the Path: Building Tomorrow's Healthcare Solutions
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 15: Recent Accolades
Recent Accolades “Export Excellence Award” BEST Economic Times by PLEXCONCIL BRANDS Best Healthcare Brands 2024 Largest Exporter of medical disposables from India Year 2021-22 & 2022-23 -; :, POLYMED
Slide 16: Way Forward
Way Forward Research & Development ▪ Targeted R&D investments towards transformative therapeutic areas, aiming to pioneer breakthrough innovations Emphasizing Inorganic Growth ▪ Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expan
Slide 17: Promising Medical Device sector
Promising Medical Device sector Govt.’s initiatives in last 5 years to bolster sector capabilities Regulatory Initiatives s Reforms s Policy on R&D and Innovation 0 PRIP Promotion of Research & Innovation in Pharma, MedTech 0 NMDP National Medical Device Policy 0 NRF Bill National Research Foundatio
Slide 18: Revenue Mix
Revenue Mix 70% International 30% India -. :» POLYMED
Slide 19: Our Strength: Consistent all-round growth
Our Strength: Consistent all-round growth ₹ ₹ 0₹ REVENUE (₹ Crs) EBIDTA (₹ Crs) PBT (₹ Crs) PAT (₹ Crs) 400.00 1600.00 500.00 344.27 300.00 1375.79 350.00 258.26 1400.00 419.50 300.00 250.00 1200.00 1115.23 400.00 237.49 179.28 923.06 303.50 250.00 200.00 1000.00 300.00 195.24 146.51 253.45 200.00 1
Slide 20: Financial Performance Comparison (Standalone & Consolidated)
Financial Performance Comparison (Standalone & Consolidated) (₹ in lacs except per share data) Standalone Consolidated Quarter Ended Quarter Ended 30.06.2024 31.03.2024 30.06.2023 30.06.2024 31.03.2024 30.06.2023 (Unaudited) (Audited) (Unaudited) (Unaudited) (Audited) (Unaudited) Total income from 3
Slide 21: Ratio's (in %)
Ratio’s (in %) ROCE ROE 25 20 18.91 22.91 18 17.26 20.94 20 16 14.51 17.48 13.56 14 15 14.05 12 10 10 8 6 5 4 2 0 0 FY 22 FY 23 FY 24 Q1 25 FY 22 FY 23 FY 24 Q1 25 -; :, POLYMED
Slide 22: Delivering on our commitment of Value Creation
£ Delivering on our commitment of Value Creation ' ~ \ - ~ \ \_ Market Capitalization (in INR Crs) Shareholder Category in % 30 June’23 30 June’24 20000.00 18527.76 Promoters 53.31 66.03 18000.00 15251.78 16000.00 14000.00 Institutional Investors 19.86 19.25 12000.00 10000.00 9105.74 9140.14 8000.00
Slide 23: Shareholders Return
Consistent Success Consistent Positive Performance over the Past 7 Quarters Shareholders Maximizing Returns • ROCE at 21.91 % Return Driving Growth Driving Growth Market Beating Performance • The NET SALES (Q) Highest at Rs 384 crs The stock has delivered Investors Returns* (3 years) a return of 109
Slide 24: Towards our Commitment to a Sustainable World
Towards our Commitment to a Sustainable World 6.14% HSD Saving 26 Pits for 30 KL Rain Harvesting; by convert Steam Boilers with 90% of the wastewater is PNG & minimize HT Line faults being reused FUEL SAVING WATER RECYCLING Power consumption per Produced Solar Energy production unit remains steady 1
Slide 25: Thank You
Poly Medicure Limited Registered Office: Thank You 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com -; :, POLYMED